Expertise in
7
conditions

Dr. Julie A. Parsons

Pediatric Neurology | Neurology
13123 E 16th Ave, 
Aurora, CO 
Accepting New Patients
Expertise in
7
conditions
13123 E 16th Ave, 
Aurora, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Julie Parsons is a Pediatric Neurologist and a Neurologist in Aurora, Colorado. Dr. Parsons is highly rated in 7 conditions, according to our data. Her top areas of expertise are Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 2, and Spinal Muscular Atrophy Type 3. Dr. Parsons is currently accepting new patients.

Her clinical research consists of co-authoring 24 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Neurology
Neurology
Licenses
Psychiatry & Neurology in CO
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

13123 E 16th Ave, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 3
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: September 07, 2022
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Biological
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

24 Total Publications

Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus: Report of the AAN Guidelines Subcommittee.
Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus: Report of the AAN Guidelines Subcommittee.
Journal: Neurology
Published: May 14, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Kelly G. Knupp
Neurology | Pediatrics | Pediatric Neurology
Expertise in
17
conditions
Dr. Kelly G. Knupp
Neurology | Pediatrics | Pediatric Neurology

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (0.1 mi)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kelly Knupp is a Neurologist and a Pediatrics provider in Aurora, Colorado. Dr. Knupp is highly rated in 17 conditions, according to our data. Her top areas of expertise are West Syndrome, Myoclonic Epilepsy, Spasmus Nutans, Dravet Syndrome, and Gastrostomy. Dr. Knupp is currently accepting new patients.

Expertise in
13
conditions
Dr. Timothy A. Benke
Pediatric Neurology | Pediatrics | Neurology
Expertise in
13
conditions
Dr. Timothy A. Benke
Pediatric Neurology | Pediatrics | Neurology

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (0.1 mi)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Timothy Benke is a Pediatric Neurologist and a Pediatrics provider in Aurora, Colorado. Dr. Benke is highly rated in 13 conditions, according to our data. His top areas of expertise are Rett Syndrome, West Syndrome, Spasmus Nutans, and CDKL5 Deficiency Disorder. Dr. Benke is currently accepting new patients.

Expertise in
11
conditions
Dr. Scott T. Demarest
Pediatric Neurology
Expertise in
11
conditions
Dr. Scott T. Demarest
Pediatric Neurology
13123 E 16th Ave, 
Aurora, CO 
 (0.1 mi)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Scott Demarest is a Pediatric Neurologist in Aurora, Colorado. Dr. Demarest is highly rated in 11 conditions, according to our data. His top areas of expertise are CDKL5 Deficiency Disorder, West Syndrome, Spasmus Nutans, and Epilepsy. Dr. Demarest is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Parsons's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile